Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Claggett

Showing results (151-160 of 361) with videos related to

Pageof 37
Sort By:
Echocardiography (Mount Kisco, N.Y.)|October 18, 2020
Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery diseaseFlemming Javier Olsen, Mats Christian Højbjerg Lassen, Philip Brainin, et al.
Diabetologia|November 4, 2017
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trialJelena P Seferovic, Marc A Pfeffer, Brian Claggett, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Circulation. Heart Failure|October 19, 2014
Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fractionAkshay S Desai, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|November 5, 2015
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarctionNa Wang, Chung-Lieh Hung, Sung-Hee Shin, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
European Journal of Heart Failure|February 7, 2015
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Carolyn S P Lam, Margaret McEntegart, Brian Claggett, et al.
Pageof 37

Showing results (151-160 of 361) with videos related to

Sort By:
Pageof 37
Echocardiography (Mount Kisco, N.Y.)|October 18, 2020
Myocardial performance index is associated with cardiac computed tomography findings in patients with suspected coronary artery diseaseFlemming Javier Olsen, Mats Christian Højbjerg Lassen, Philip Brainin, et al.
Diabetologia|November 4, 2017
Three-question set from Michigan Neuropathy Screening Instrument adds independent prognostic information on cardiovascular outcomes: analysis of ALTITUDE trialJelena P Seferovic, Marc A Pfeffer, Brian Claggett, et al.
European Journal of Heart Failure|November 18, 2017
Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trialSenthil Selvaraj, Brian Claggett, Sanjiv J Shah, et al.
Circulation. Heart Failure|October 19, 2014
Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fractionAkshay S Desai, Brian Claggett, Marc A Pfeffer, et al.
European Heart Journal|November 5, 2015
Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarctionNa Wang, Chung-Lieh Hung, Sung-Hee Shin, et al.
JACC. Heart Failure|January 10, 2016
Influenza Vaccination in Patients With Chronic Heart Failure: The PARADIGM-HF TrialOrly Vardeny, Brian Claggett, Jacob A Udell, et al.
European Journal of Heart Failure|February 12, 2019
Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM-HF trialOrly Vardeny, Brian Claggett, Jessica Kachadourian, et al.
European Journal of Heart Failure|May 15, 2020
Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fractionKota Suzuki, Brian Claggett, Masatoshi Minamisawa, et al.
Journal of Cardiac Failure|March 25, 2018
Incident Hyperkalemia, Hypokalemia, and Clinical Outcomes During Spironolactone Treatment of Heart Failure With Preserved Ejection Fraction: Analysis of the TOPCAT TrialAkshay S Desai, Jiankang Liu, Marc A Pfeffer, et al.
European Journal of Heart Failure|February 7, 2015
Sex differences in clinical characteristics and outcomes after myocardial infarction: insights from the Valsartan in Acute Myocardial Infarction Trial (VALIANT)Carolyn S P Lam, Margaret McEntegart, Brian Claggett, et al.
Pageof 37